Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 21.87 USD -8.88% Market Closed
Market Cap: 154.2m USD

EV/EBIT
Enterprise Value to EBIT

-0.6
Current
-0.7
Median
4.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.6
=
Enterprise Value
27.1m USD
/
EBIT
-45.3m USD
Market Cap EV/EBIT
US
Cidara Therapeutics Inc
NASDAQ:CDTX
154.1m USD -0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -221 001.2
US
Abbvie Inc
NYSE:ABBV
313.6B USD 23.6
US
Amgen Inc
NASDAQ:AMGN
144.4B USD 30.8
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 9.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.4B USD 22.5
US
Epizyme Inc
F:EPE
94.1B EUR -491.9
AU
CSL Ltd
ASX:CSL
135.3B AUD 24.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD 16.8
US
Seagen Inc
F:SGT
39.3B EUR -52.1
NL
argenx SE
XBRU:ARGX
38.2B EUR -107.4
EBIT Growth EV/EBIT to Growth
US
Cidara Therapeutics Inc
NASDAQ:CDTX
Average EV/EBIT: 21.3
Negative Multiple: -0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -221 001.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.8
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.9 N/A N/A
AU
CSL Ltd
ASX:CSL
24.4
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.4 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.2
2-Years Forward
EV/EBIT
-0.3
3-Years Forward
EV/EBIT
-0.2